DrugPatentWatch Database Preview
Merck Sharp Dohme Company Profile
» See Plans and Pricing
US Patents for Merck Sharp Dohme
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 10,001,483 | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | Orphan | search |
Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 10,004,812 | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | Orphan | search |
Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 10,017,492 | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | Orphan | search |
Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 10,092,645 | MedImmune Limited (Cambridge, GB) | 2034-06-17 | RX | Orphan | search |
Merck Sharp Dohme | KEYTRUDA | pembrolizumab | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER | 125514 | 001 | 2014-09-04 | 10,100,034 | Advenchen Pharmaceuticals, LLC (Moorpark, CA) | 2035-05-04 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
This search can help find similar names.